Noom MedvsRo Body Program

Noom Med combines two things. First, a licensed clinician reviews an online health assessment and, if appropriate, prescribes a weight-management medication: a compounded or brand-name GLP-1 receptor agonist (semaglutide, the active ingredient in Ozempic/Wegovy), a dual GLP-1/GIP receptor agonist (tirzepatide, the active ingredient in Mounjaro/Zepbound), or an oral option such as metformin. GLP-1 medications mimic a gut hormone that curbs appetite, slows stomach emptying so you feel full longer, and helps regulate blood sugar; tirzepatide adds a second incretin pathway (GIP). Metformin works differently, mainly by reducing the liver's glucose output and improving insulin sensitivity. Second, the Noom app delivers daily cognitive-behavioral-therapy-style lessons on food psychology, habit formation, and emotional eating, plus 1:1 and group coaching, to support the lifestyle changes that help weight-loss results last.

After an online visit, a licensed provider determines eligibility and can prescribe an FDA-approved GLP-1 such as the Wegovy pen, oral Wegovy, or Zepbound (with compounded options also available). These drugs target gut hormone receptors to reduce appetite and slow digestion. Ro layers on a 12-month coaching curriculum (nutrition, exercise, sleep, habits), monthly provider check-ins, messaging, and lab testing when ordered.

The medications Noom prescribes carry strong trial evidence, though that evidence comes from the full-dose, FDA-approved products rather than compounded or microdose versions. In the STEP 1 trial (New England Journal of Medicine, 2021), once-weekly semaglutide 2.4 mg plus lifestyle intervention produced a mean 14.9% body-weight loss at 68 weeks versus 2.4% with placebo, with about 69% of treated participants losing at least 10% of their body weight. In SURMOUNT-1 (New England Journal of Medicine, 2022), tirzepatide produced average weight loss of roughly 16.0% to 22.5% depending on dose. Important caveats: Noom's lower-priced plans use compounded GLP-1s, and its Microdose plan deliberately uses doses below the standard maintenance levels studied in these trials, so individual results may be smaller than the headline trial figures. Noom's own 2026 engagement report (observational, 14,203 GLP-1 program members) found that the most-engaged app users lost about 8.3 lbs more by week 40 and stayed on their medication roughly twice as long (about 2.2x) over the first year compared with the least engaged, but the company itself notes this shows correlation, not proof that the app causes the difference. Individual results vary.

Ro prescribes the GLP-1 medications backed by the strongest evidence: semaglutide produced roughly 15% mean weight loss in STEP 1 and tirzepatide up to about 21% in SURMOUNT-1, with the head-to-head SURMOUNT-5 trial favoring tirzepatide (~20% vs ~14%). Real-world results depend on the medication, dose, and adherence; individual results vary.

The most common GLP-1 and tirzepatide side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and reflux, usually worst when starting or increasing the dose and often easing over time. Lower-dose (microdose) regimens are marketed partly to blunt these effects, though that benefit is not established in large trials. Serious but less common risks include pancreatitis, gallbladder problems such as gallstones, kidney injury from dehydration, and, in rodent studies, thyroid C-cell tumors, which is why these drugs carry a boxed warning; a causal link to thyroid cancer in humans has not been established. A specific concern with compounded semaglutide: the FDA has warned of dosing errors in which patients received 5 to 20 times the intended dose from multi-dose vials, with adverse events including severe vomiting, fainting, dehydration, and some hospitalizations. Follow dosing instructions exactly, report severe or persistent abdominal pain promptly, and seek medical care for any serious reaction.

Expect common GI side effects (nausea, vomiting, diarrhea or constipation), most pronounced during dose escalation. Serious but rare risks include pancreatitis and gallbladder disease. Provider check-ins and labs help monitor safety. This is educational information, not medical advice.

As of 2026, Noom Med medication-included plans (priced after a discounted first month and typically billed quarterly) run roughly: the Weight-Loss Pill (metformin) plan around $99/month, the compounded GLP-1Rx plan around $129/month, the compounded Microdose GLP-1Rx plan around $199/month, and the tirzepatide dual-agonist GLP-1Rx Plus plan around $299/month. A separate telehealth tier (around $99/month after the first month) covers clinician care and the app for brand-name drugs such as Ozempic, Wegovy, Mounjaro, or Zepbound, but the medication itself is billed separately through insurance or cash pay (brand-name GLP-1s can list at roughly $1,000 or more per month without coverage). Plans are generally FSA/HSA-eligible. Insurance rarely covers the bundled program or compounded drugs, so expect this to be a recurring out-of-pocket cost; confirm current pricing on Noom's site before enrolling, as plans and prices change.

As of 2026, membership is $39 for the first month, then $149/mo monthly or as low as ~$74/mo with annual prepay. Medication is separate: oral Wegovy from ~$149/mo, Wegovy pen ~$199/mo introductory then up to $349/mo at higher doses, and Zepbound KwikPen cash-pay ~$449/mo. Drug pricing and promos change often.

Noom Med is aimed at US adults who qualify for prescription weight management, typically a BMI of 30 or higher (obesity) or 27 or higher (overweight) with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea; final eligibility is determined by the clinician after intake, and clinical guidelines, not a website, govern who should be treated. It is not appropriate for people who are pregnant or breastfeeding, those with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, those with a history of pancreatitis, or anyone with known hypersensitivity to the prescribed drug. Anyone with gallbladder disease, diabetic retinopathy, severe kidney or liver disease, or significant gastrointestinal disorders should disclose this to the clinician. People who specifically want an FDA-approved drug should choose the brand-name telehealth tier rather than the compounded plans. The compounded Microdose plan is also unavailable in some states (such as Alabama, Arkansas, Iowa, Louisiana, and Mississippi) due to state rules on compounded medications.

Eligibility is determined by a licensed provider after an online visit, generally following GLP-1 prescribing guidelines (typically BMI 30+, or 27+ with a weight-related condition). The program is offered on a cash-pay basis with multiple medication formats.